- Report
- February 2026
- 250 Pages
Global
From €4202EUR$4,490USD£3,513GBP
- Report
- December 2025
- 150 Pages
Global
From €4539EUR$4,850USD£3,794GBP
- Report
- September 2026
- 196 Pages
Global
From €3318EUR$3,545USD£2,773GBP
€3687EUR$3,939USD£3,082GBP
- Report
- February 2026
- 250 Pages
Global
From €4202EUR$4,490USD£3,513GBP
- Report
- February 2026
- 250 Pages
Global
From €4202EUR$4,490USD£3,513GBP
- Report
- July 2026
- 190 Pages
Global
From €7478EUR$7,990USD£6,251GBP
- Report
- July 2026
- 250 Pages
Global
From €7478EUR$7,990USD£6,251GBP
- Drug Pipelines
- May 2026
- 150 Pages
Global
From €2610EUR$2,789USD£2,182GBP
- Report
- May 2026
- 400 Pages
Global
From €4632EUR$4,949USD£3,872GBP
- Report
- March 2026
- 148 Pages
Global
From €3743EUR$3,999USD£3,129GBP
- Report
- May 2023
- 190 Pages
Global
From €2293EUR$2,450USD£1,917GBP
- Report
- November 2025
- 150 Pages
Global
From €5569EUR$5,950USD£4,655GBP
- Report
- November 2023
- 135 Pages
Global
From €3744EUR$4,000USD£3,129GBP
- Clinical Trials
- April 2025
- 250 Pages
Global
From €2808EUR$3,000USD£2,347GBP
- Drug Pipelines
- April 2025
- 240 Pages
Global
From €2808EUR$3,000USD£2,347GBP
- Drug Pipelines
- April 2025
- 200 Pages
Global
From €4680EUR$5,000USD£3,912GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €2340EUR$2,500USD£1,956GBP
- Clinical Trials
- April 2025
- 75 Pages
Global
From €1404EUR$1,500USD£1,173GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3042EUR$3,250USD£2,543GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2574EUR$2,750USD£2,151GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more